CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 22 enrolled
Drug / intervention
buspironedrug
Likely dose
buspirone 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02363478
NCT02363478Early Ph 1Completed
CompareCT.gov

Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)

Laikο General Hospital, Athens·interventional·Posted Feb 16, 2015·Updated Oct 24, 2016

In Brief

A Early Phase 1 clinical trial evaluating buspirone for Systemic Sclerosis. Completed, enrolled 22 participants across 1 site.

Detailed Summary

Esophagus is commonly affected in Systemic Sclerosis (SSc) and esophageal function is compromised in about 75% of patients. Previous studies have shown that buspirone, an orally available 5-HT1A (serotonin 1a receptor agonist), enhances esophageal motility in healthy volunteers. Recently, the investigators observed that a single dose of buspirone (10mg) improves lower esophageal sphincter (LES) function in patients with SSc and esophageal involvement . Objectives: To evaluate the effect of continuous administration of buspirone on esophageal dysfunction and related symptoms in SSc using high resolution manometry (HRM).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Sclerosis
CountriesGreece
Collaborators--

Timeline

Early Ph 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 16, 2015
Enrollment StartDec 1, 2014
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 11.4 years ago

Interventions

buspironedrug

buspirone 10 mg X2 for 4 weeks